Clinical data with COX-1 and COX-2 inhibitors: What possible alerts in pharmacovigilance?;Les inhibiteurs de COX-1 et COX-2, donnees cliniques: Quelles alertes possibles en pharmacovigilance?

Therapie

Volumn 55, Issue 1, 2000, Pages 21-28

  Larousse, C ^a   Veyrac, G ^a  

^a INSTITUT DE BIOLOGIE   (France)

Author keywords

COX 1 inhibitors; NSAIDs; Pharmacovigilance; Preferential COX 2 inhibitors; Selective COX 2 inhibitors

Indexed keywords

AZAPROPAZONE; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; INDOMETACIN; KETOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; TIAPROFENIC ACID;

ALZHEIMER DISEASE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; GASTROINTESTINAL HEMORRHAGE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; KIDNEY DISEASE; MORTALITY; PREMATURE LABOR; PRIORITY JOURNAL; STOMACH ULCER;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0034072709     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (63)

1. Terlain B. Efficacy and tolerance of NSAIDs: what future for COX-1 and COX-2 inhibitors? Therapie 1999; 54: 278.
2. Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998; 104 (3A): 23S-29S.
3. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991; 28(Suppl): 6-10.
4. Fries JF, Miller SR, Spitz PW et al. Toward an epidemiology of gastropathy associated with nonsteroidal anti-inflammatory drug use. Gastroenterology 1989; 96: 647-655.
5. Langman MJ, Weil J, Wainwright P et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-1078.
6. Rodriguez LAG, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non steroidal anti-inflammatory drugs. Lancet 1994; 343: 769-772.
7. Revell S, Fenney L. Impossible to state which NSAID is safer. BMJ 1995; 311: 54-55.
8. Jouzeau JY, Terlain B, Abid A et al. Cyclo-oxygenases isoenzymes: how recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 1997; 54: 563-582.
9. Eversmeyer W, Poland M, De Lapp RE et al. Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. Am J Med 1993; 95 Suppl 2A: 105-185.
10. Barner A. Review of clinical trials and benefit/risk ratio of meloxicam. Scand J Rheumatol 1996; 102: 29-37.
11. Distel M, Mueller C, Bluhumki E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 1996; 35(1): 68-77.
12. Anonyme. Meloxicam: gastrointestinal and skin reactions. WHO ADR Newsletter 1998; 4: 9.
13. Ehrich E, Dallob A, Hecken AV et al. Demonstration of selective COX-2 inhibition by MK-966 in humans. Arthritis Rheum 1996; 39(9): A328.
14. Ehrich E, Mehlisch D, Perkins S et al. Efficacy of MK-966, a highly selective inhibitor of COX-2, in the treatment of postoperative dental pain. Arthritis Rheum 1996; 39(9): A329.
15. Ehrich E, Schnitzer T, Kivitz A et al. MK966, a highly selective COX-2 inhibitor, was effective in the treatment of osteoarthritis (OA) of the knee and hip in a 6-week placebo controlled study. Arthritis Rheum 1996; 39(9): A330.
16. Zeng Q, Ehrich E, Schnitzer T, Bolognese J. A direct comparison of the precision and sensitivity of Likert and visual analog response scales in a placebo controlled study of patients with osteoarthritis of the knee. Arthitis Rheum 1996; 39(9): A1228.
17. Hubbard RC, Koepp RJ, Yu S et al. SC-58635 (Celecoxib), a novel COX-2 selective inhibitor, is effective as a treatment for osteoarthritis (OA) in a short-term pilot study. Arthritis Rheum 1996; S226: 1188.
18. Hubbard RC, Koepp R, Yu S et al. Pilot efficacy of SC-58635, a COX-2 selective inhibitor, in rheumatoid arthritis. Arthritis Rheum 1997; 40(551): 125.
19. Mehlisch DR, Hubbard RC, Isakson P et al. Analgesic efficacy and plasma levels of a highly selective inhibitor of COX-2 (SC-58635,SC) in patients with post-surgical dental pain. J Clin Pharmacol Ther 1997; 61(2): 195.
20. Geis GS, Hubbard R, Callison D et al. Safety and efficacy of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum 1998; S364: A 1990.
21. Geis GS, Syead H, Morant S et al. Efficacy and safety of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum 1998; S316: A1699.
22. Lee SS, Lanza FL, Lipsky PE et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998; 41(9): 1591-1602.
23. Lanza FL, Rack MF, Callison DA et al. A pilot endoscopic study of the gastroduodenal effects of SC-58635, a novel COX-2 selective inhibitor. Gastroenterology 1997; 112(4): A194.
24. Zhao SZ, Hatoum HT, Hubbard RC et al. Effect of celecoxib, a novel COX-2 inhibitor, on health-related quality of life of patients with osteoarthritis of the knee. Arthritis Rheum 1997; 40(9): suppl S88.
25. Lanza F, Simon T, Quan H et al. Selective inhibition of cyclooxygenase-2 (COX-2) with MK-0966 (250 mg Q.D.) is associated with less gastroduodenal damage than aspirin (ASA) 650 mg Q.I.D. or ibuprofen (IBU) 800 mg T.I.D. Gastroenterology 1997; 112(4): A194.
26. Mizuno H, Sakamoto C, Matsuda K et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997; 112: 387-397.
27. Shigeta JI, Takahashi S, Okabe S. Role of cyclooxygenase-2 in the healing of gastric ulcers in rats. J Pharmacol Exp Ther 1998; 286(3): 1383-1390.
28. Gretzer B, Ehrlich K, Maricic N et al. Selective cyclooxygenase-2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach. Br J Pharmacol 1998; 123: 927-935.
29. O'Neil GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993; 330: 156-160.
30. Harris RC, McKanna JA, Akai Y et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest. 1994; 94: 2504-2510.
31. Hartner A, Goppelt-Struebe M, Hilgers KF. Coordinate expression of cyclooxygenase-2 and renin in the rat kidney in renovascular hypertension. Hypertension 1997; 31: 201-205.
32. Brooks DP, Adams J, DePalma PD et al. The selective cyclooxygenase-2 inhibitor, celecoxib, but not 6-MNA, affects renal hemodynamic and renal function in the dog. J Rheum 1998; 25(52): M64.
33. Dinchuk JE, Car BD, Focht RJ et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995; 378: 406-409.
34. Tomasoni S, Noris M, Zapella S et al. Upregulation of renal and systemic cyclooxygenase-2 in patients with active Lupus nephritis. J Am Soc Nephrol 1998; 9: 1202-1212.
35. Kömhoff M, Gröne HJ, Klein T et al. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Ameriran Physiological Society 1997; F460-F468.
36. Kaufmann WE, Worley PF, Pegg J et al. COX-2, a synaptically-induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 1996; 93: 2317-2321.
37. Breder CD, Smith WL, Raz A et al. Distribution and characterization of cyclooxygenase immunoreactivity in the ovine brain. J Comp Neurol 1992; 322: 409-438.
38. Yamagata K, Andreasson KI, Kaufmann WI et al. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993; 11: 371-386.
39. Breder CD, DeWitt D, Kraig RP. Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol 1995; 355: 196-315.
40. O'Banion MK, Dusel JC, Chang JW et al. Interleukin-1b induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures. J Neurochem 1996; 66: 2532-2540.
41. Bauer MKA, Lieb K, Schulze-Osthoff K et al. Expression and regulation of cyclooxygenase-2 in rat microglia. Eur J Biochem 1997; 243: 726-731.
42. 2. Proc Natl Acad Sci USA 1997; 94: 6500-6505.
43. Breitner JCS. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Ann Rev Med 1996; 47: 401-411.
44. Bennett WM, Heinrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis 1996; 28(1): S56-S62.
45. Whelton A. Renal effects of over-the-counter analgesics. J Clin Pharmarol 1995; 35: 454-463.
46. Stichtenoth DO, Froelich JC. Avoidance of renal side effects of non-steroidal anti-inflammatory drugs: value of selective cyclooxygenase-2 inhibition. In: Vane JR, Botting RM, eds. Clinical Significance and Potential of Selective COX-2 Inhibitors. London: William Harvey Press, 1998: 99-108.
47. Venturini CM, Isakson P, Needleman P. Non-steroidal anti-inflammatory drug induced renal failure: a brief review of the role of cyclo-oxygenase isoforms. Curr Opin Nephrol Hypertension 1998; 7: 79-82.
48. Hedin L, Gaddy-Kurten D, Kurten R et al. Prostaglandin endoperoxide synthase in rat ovarian follicles: content, cellular distribution and evidence for hormonal induction preceding ovulation. Endocrinology 1987; 121: 722-731.
49. Sirois J, Richard JS. Purification and characterization of a novel, distinct isoform of prostaglandin endoperoxide synthase induced by human chorionic gonatropin in granulosa cells of rat preovulatory follicles. J Biol Chem 1992; 267: 6382-6388.
50. Lim H, Paria B, Das K et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997; 91: 197-208.
51. Murdoch WJ. Disruption of cellular associations within the granulosa compartment of periovulatory ovine follicles: relationship to maturation of the oocyte and regulation by prostaglandins. Cell Tissue Res 1988; 252: 459-462.
52. Chakraborty I, Das SK, Wang J, Dey SK. Developmental expression of the cyclooxygenase-1 and cyclooxygenase-2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids. J Mol Endocrinol 1996; 16: 107-122.
53. Han SW, Lei ZM, Rao ChV. Up-regulation of cyclooxygenase-2 gene expression by chorionic gonadotropin during the differentiation of human endometrial stromal cells into decidua. Endocrinology 1996; 137(5): 1791-1797.
54. Charpigny G, Reinaud P, Tamby JP et al. Cyclooxygenase-2 unlike cyclooxygenase-1 is highly expressed in ovine embryos during the implantation period. Biol Reprod 1997; 57: 1032-1040.
55. Slater DM, Berger LC, Newton R et al. Expression of cyclooxygenase types 1 and 2 in human fetal membranes at term. Am J Obstet Gynecol 1995; 172(1): 77-82.
56. Gibb W, Sun M. Localization of prostaglandin synthase type 2 protein and mRNA in term human fetal membranes and decidua. J Endocrinol 1996; 150: 497-503.
57. Wimsatt J, Nathanielsz PW, Sirois J. Induction of prostanglandin endoperoxide synthase isoform-2 on ovine cotyledonary tissues during late gestation. Endocrinology 1993; 133: 1068-1073.
58. Bennett P, Sawdy R, Slater D. The role of cyclooxygenase-2 in reproduction. In: Vane JR, Botting RM, eds. Clinical Significance and Potential of Selective COX-2 Inhibitors. London: William Harvey Press, 1998: 171-183.
59. Sawdy R, Slater D, Fisk N et al. Use of a cyclo-oxygenase type-2-selective non-steroidal anti-inflammatory agent to prevent preterm delivery. Lancet 1997; 350: 265-266.
60. Mengle-Gaw L, Hubbard RC, Karim A et al. A study of the platelet effects of SC-58635, a novel COX-2 selective inhibitor. Arthritis Rheum 1997, 40(9) suppl S93.
61. Kutchera W, Jones DA, Matsunami N et al. Prostaglandin H syntase 2 is expressed abnormally in human colon. Cancer Res 1995; 55: 1556-1559.
62. Wallace JL. Selective COX-2 inhibitors: is the water becoming muddy? TIPS 1999; 20: 4-6.
63. Pairet M, Netter P et al. Inhibiteurs sélectifs de la cyclooxygénase de type 2 (COX-2): intérêts et limites. Therapie 1999; 54: 433-445.